

Nancy K Sweitzer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11531622/publications.pdf>

Version: 2024-02-01

87
papers

7,911
citations

81900

39
h-index

62596

80
g-index

87
all docs

87
docs citations

87
times ranked

7984
citing authors

#	ARTICLE	IF	CITATIONS
1	Is the affordable care act medicaid expansion associated with receipt of heart failure guideline-directed medical therapy by race and ethnicity?. American Heart Journal, 2022, 244, 135-148.	2.7	10
2	Looking Ahead: Circulation: Heart Failure in 2022. Circulation: Heart Failure, 2022, 15, e009405.	3.9	1
3	Economic Issues in Heart Failure in the United States. Journal of Cardiac Failure, 2022, 28, 453-466.	1.7	40
4	Whole transcriptome profiling of prospective endomyocardial biopsies reveals prognostic and diagnostic signatures of cardiac allograft rejection. Journal of Heart and Lung Transplantation, 2022, 41, 840-848.	0.6	9
5	Grace Under Pressure. Circulation: Heart Failure, 2022, 15, CIRCHEARTFAILURE122009513.	3.9	0
6	The association between heart rate behavior and gait performance: The moderating effect of frailty. PLoS ONE, 2022, 17, e0264013.	2.5	2
7	Relationships between 2018 UNOS heart policy and transplant outcomes in metropolitan, micropolitan, and rural settings. Journal of Heart and Lung Transplantation, 2022, 41, 1228-1236.	0.6	3
8	Ex Ante Economic Evaluation of Arg389 Genetically Targeted Treatment with Bucindolol versus Empirical Treatment with Carvedilol in NYHA III/IV Heart Failure. American Journal of Cardiovascular Drugs, 2021, 21, 205-217.	2.2	3
9	Imbalance in Heart Transplant to Heart Failure Mortality Ratio Among African American, Hispanic, and White Patients. Circulation, 2021, 143, 2412-2414.	1.6	18
10	Imbalance in Heart Transplant to Heart Failure Mortality Ratio by Sex. Journal of the American Heart Association, 2021, 10, e020146.	3.7	7
11	Sex Disparities in Organ Donation: Finding an Equitable Donor Pool. Journal of the American Heart Association, 2021, 10, e020820.	3.7	6
12	Clinical Outcome Predictions for the VeriCiguaT Global Study in Subjects With Heart Failure With Reduced Ejection Fraction (VICTORIA) Trial. Journal of Cardiac Failure, 2021, 27, 949-956.	1.7	8
13	Association of Hyper-Polypharmacy With Clinical Outcomes in Heart Failure With Preserved Ejection Fraction. Circulation: Heart Failure, 2021, 14, e008293.	3.9	18
14	2021: A Look Back. Circulation: Heart Failure, 2021, 14, e009358.	3.9	0
15	Impact of pulmonary disease on the prognosis in heart failure with preserved ejection fraction: the TOPCAT trial. European Journal of Heart Failure, 2020, 22, 557-559.	7.1	5
16	Association of Gender and Race With Allocation of Advanced Heart Failure Therapies. JAMA Network Open, 2020, 3, e2011044.	5.9	91
17	Showcasing Heart Failure Science at the American Heart Association Scientific Sessions. Circulation: Heart Failure, 2020, 13, e008157.	3.9	0
18	Is the Affordable Care Act Medicaid Expansion Linked to Change in Rate of Ventricular Assist Device Implantation for Blacks and Whites?. Circulation: Heart Failure, 2020, 13, e006544.	3.9	14

#	ARTICLE	IF	CITATIONS
19	Science in the Time of Coronavirus. <i>Circulation: Heart Failure</i> , 2020, 13, e007115.	3.9	0
20	Choosing a Career in Heart Failure. <i>Circulation: Heart Failure</i> , 2019, 12, e006139.	3.9	2
21	Impact of Malnutrition Using Geriatric Nutritional Risk Index in Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2019, 7, 664-675.	4.1	68
22	Application of the H ₂ FPEF score to a global clinical trial of patients with heart failure with preserved ejection fraction: the TOPCAT trial. <i>European Journal of Heart Failure</i> , 2019, 21, 1288-1291.	7.1	18
23	Heart Transplantation Survival and the Use of Traumatically Brain-Injured Donors: UNOS Registry Propensity-Matched Analysis. <i>Journal of the American Heart Association</i> , 2019, 8, e012894.	3.7	9
24	Medical Misinformation: Vet the Message!. <i>Journal of the American Heart Association</i> , 2019, 8, e011838.	3.7	15
25	Utility of the Cardiovascular Physical Examination and Impact of Spironolactone in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2019, 12, e006125.	3.9	21
26	Sex Differences in Outcomes and Responses to Spironolactone in Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2019, 7, 228-238.	4.1	123
27	Influence of Age on Efficacy and Safety of Spironolactone in Heart Failure. <i>JACC: Heart Failure</i> , 2019, 7, 1022-1028.	4.1	6
28	Baseline features of the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 382	7.1	65
29	Does Race Influence Decision Making for Advanced Heart Failure Therapies?. <i>Journal of the American Heart Association</i> , 2019, 8, e013592.	3.7	108
30	Comparison of Outcomes in Patients With Diabetes Mellitus Treated With Versus Without Insulin+ Heart Failure With Preserved Left Ventricular Ejection Fraction (from the TOPCAT Study). <i>American Journal of Cardiology</i> , 2019, 123, 611-617.	1.6	21
31	Factors Related to Physician Clinical Decision-Making for African-American and Hispanic Patients: a Qualitative Meta-Synthesis. <i>Journal of Racial and Ethnic Health Disparities</i> , 2018, 5, 1215-1229.	3.2	49
32	Sudden Death in Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2018, 6, 653-661.	4.1	56
33	When the VEST Does Not Fit. <i>Circulation: Heart Failure</i> , 2018, 11, e005116.	3.9	2
34	Apophenia and the Crafting of a Circulation: Heart Failure Issue. <i>Circulation: Heart Failure</i> , 2018, 11, e005027.	3.9	0
35	New Therapeutic Target in Heart Failure. <i>Circulation</i> , 2018, 137, 1331-1333.	1.6	4
36	Racial Differences in Characteristics and Outcomes of Patients With Heart Failure and Preserved Ejection Fraction in the Treatment of Preserved Cardiac Function Heart Failure Trial. <i>Circulation: Heart Failure</i> , 2018, 11, e004457.	3.9	31

#	ARTICLE	IF	CITATIONS
37	Incident Hyperkalemia, Hypokalemia, and Clinical Outcomes During Spironolactone Treatment of Heart Failure With Preserved Ejection Fraction: Analysis of the TOPCAT Trial. <i>Journal of Cardiac Failure</i> , 2018, 24, 313-320.	1.7	49
38	Influence of ejection fraction on cause-specific mortality in heart failure with preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2018, 20, 815-816.	7.1	5
39	Systolic blood pressure and cardiovascular outcomes in heart failure with preserved ejection fraction: an analysis of the TOPCAT trial. <i>European Journal of Heart Failure</i> , 2018, 20, 483-490.	7.1	28
40	Ex ante economic evaluation of genetic testing for the ARG389 beta1-adrenergic receptor polymorphism to support bucindolol treatment decisions in Stage III/IV heart failure. <i>Expert Review of Precision Medicine and Drug Development</i> , 2018, 3, 319-329.	0.7	3
41	Prognostic Value of Albuminuria and Influence of Spironolactone in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2018, 11, e005288.	3.9	35
42	Thyroid Dysfunction in Heart Failure and Cardiovascular Outcomes. <i>Circulation: Heart Failure</i> , 2018, 11, e005266.	3.9	143
43	The frailty syndrome and outcomes in the TOPCAT trial. <i>European Journal of Heart Failure</i> , 2018, 20, 1570-1577.	7.1	106
44	Temporal Trends in Contemporary Use of Ventricular Assist Devices by Race and Ethnicity. <i>Circulation: Heart Failure</i> , 2018, 11, e005008.	3.9	58
45	Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial. <i>Circulation: Heart Failure</i> , 2018, 11, e004962.	3.9	117
46	Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2018, 6, 689-697.	4.1	68
47	Association of Natriuretic Peptides With Cardiovascular Prognosis in Heart Failure With Preserved Ejection Fraction. <i>JAMA Cardiology</i> , 2018, 3, 1000.	6.1	41
48	Physical Activity and Prognosis in the TOPCAT Trial (Treatment of Preserved Cardiac Function Heart) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	9.6	80
49	More Appropriate Cardiovascular Risk Screening Through Understanding Complex Phenotypes. <i>Journal of the American College of Cardiology</i> , 2017, 70, 1438-1440.	2.8	5
50	Editor's Perspective. <i>Circulation: Heart Failure</i> , 2017, 10, .	3.9	0
51	From statistical significance to clinical relevance: A simple algorithm to integrate brain natriuretic peptide and the Seattle Heart Failure Model for risk stratification in heart failure. <i>Journal of Heart and Lung Transplantation</i> , 2016, 35, 714-721.	0.6	15
52	Prognostic Relevance of Left Atrial Dysfunction in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2016, 9, e002763.	3.9	224
53	Effect of Heart Failure With Preserved Ejection Fraction on Nitric Oxide Metabolites. <i>American Journal of Cardiology</i> , 2016, 118, 1855-1860.	1.6	15
54	Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. <i>European Heart Journal</i> , 2016, 37, 455-462.	2.2	396

#	ARTICLE	IF	CITATIONS
55	Prognostic Value of Galectin-3 for Adverse Outcomes in Chronic Heart Failure. <i>Journal of Cardiac Failure</i> , 2016, 22, 256-262.	1.7	46
56	Regional Variation in Patients and Outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) Trial. <i>Circulation</i> , 2015, 131, 34-42.	1.6	758
57	Prognostic Importance of Impaired Systolic Function in Heart Failure With Preserved Ejection Fraction and the Impact of Spironolactone. <i>Circulation</i> , 2015, 132, 402-414.	1.6	371
58	Heart Failure in Non-Caucasians, Women, and Older Adults: A White Paper on Special Populations From the Heart Failure Society of America Guideline Committee. <i>Journal of Cardiac Failure</i> , 2015, 21, 674-693.	1.7	39
59	Prognostic Importance of Changes in Cardiac Structure and Function in Heart Failure With Preserved Ejection Fraction and the Impact of Spironolactone. <i>Circulation: Heart Failure</i> , 2015, 8, 1052-1058.	3.9	70
60	Effect of Renal Function on Prognosis in Chronic Heart Failure. <i>American Journal of Cardiology</i> , 2015, 115, 62-68.	1.6	21
61	Cardiac Structure and Function in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2014, 7, 104-115.	3.9	288
62	Cardiac Structure and Function and Prognosis in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2014, 7, 740-751.	3.9	218
63	Lack of Persistence of Influenza Vaccine Antibody Titers in Patients With Heart Failure. <i>Journal of Cardiac Failure</i> , 2014, 20, 105-109.	1.7	15
64	Spironolactone for Heart Failure with Preserved Ejection Fraction. <i>New England Journal of Medicine</i> , 2014, 370, 1383-1392.	27.0	1,993
65	Heart Failure With Recovered Ejection Fraction. <i>Circulation</i> , 2014, 129, 2380-2387.	1.6	244
66	Strain Improves Risk Prediction Beyond Ejection Fraction in Chronic Systolic Heart Failure. <i>Journal of the American Heart Association</i> , 2014, 3, e000550.	3.7	81
67	Biomarker Predictors of Cardiac Hospitalization in Chronic Heart Failure: A Recurrent Event Analysis. <i>Journal of Cardiac Failure</i> , 2014, 20, 569-576.	1.7	26
68	Left Ventricular Responses to Acute Changes in Late Systolic Pressure Augmentation in Older Adults. <i>American Journal of Hypertension</i> , 2013, 26, 866-871.	2.0	10
69	Ventricular-Arterial Coupling, Remodeling, and Prognosis in Chronic Heart Failure. <i>Journal of the American College of Cardiology</i> , 2013, 62, 1165-1172.	2.8	189
70	Acute Decompensated Heart Failure: Update on New and Emerging Evidence and Directions for Future Research. <i>Journal of Cardiac Failure</i> , 2013, 19, 371-389.	1.7	53
71	Baseline Characteristics of Patients in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial. <i>Circulation: Heart Failure</i> , 2013, 6, 184-192.	3.9	154
72	Continuing Medical Education Activity in Echocardiography. <i>Echocardiography</i> , 2013, 30, 512-512.	0.9	1

#	ARTICLE	IF	CITATIONS
73	Double dose vs. standard dose influenza vaccination in patients with heart failure: a pilot study. <i>European Journal of Heart Failure</i> , 2013, 15, 560-564.	7.1	25
74	Multiple Biomarkers for Risk Prediction in Chronic Heart Failure. <i>Circulation: Heart Failure</i> , 2012, 5, 183-190.	3.9	169
75	The Vascular Marker Soluble Fms-Like Tyrosine Kinase 1 Is Associated With Disease Severity and Adverse Outcomes in Chronic Heart Failure. <i>Journal of the American College of Cardiology</i> , 2011, 58, 386-394.	2.8	65
76	Determinants of Exercise Intolerance in Heart Failure With Preserved Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2011, 58, 2547-2548.	2.8	4
77	Decreased Cardiac Functional Reserve in Heart Failure With Preserved Systolic Function. <i>Journal of Cardiac Failure</i> , 2011, 17, 301-308.	1.7	55
78	High-Sensitivity ST2 for Prediction of Adverse Outcomes in Chronic Heart Failure. <i>Circulation: Heart Failure</i> , 2011, 4, 180-187.	3.9	319
79	Loss-of-function DNA sequence variant in the <i>CLCNKA</i> chloride channel implicates the cardio-renal axis in interindividual heart failure risk variation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 2456-2461.	7.1	95
80	Decreased T-Cell Responses to Influenza Vaccination in Patients with Heart Failure. <i>Pharmacotherapy</i> , 2010, 30, 10-16.	2.6	21
81	Neuregulin-1 ² Is Associated With Disease Severity and Adverse Outcomes in Chronic Heart Failure. <i>Circulation</i> , 2009, 120, 310-317.	1.6	103
82	Decreased Immune Responses to Influenza Vaccination in Patients With Heart Failure. <i>Journal of Cardiac Failure</i> , 2009, 15, 368-373.	1.7	40
83	Re: Decreased Immune Responses to Influenza Vaccination in Patients With Heart Failure. <i>Journal of Cardiac Failure</i> , 2009, 15, 549-551.	1.7	0
84	Comparison of Clinical Features and Outcomes of Patients Hospitalized With Heart Failure and Normal Ejection Fraction (≥55%) Versus Those With Mildly Reduced (40% to 55%) and Moderately to Severely Reduced (<40%) Fractions. <i>American Journal of Cardiology</i> , 2008, 101, 1151-1156.	1.6	126
85	Increases in Central Aortic Impedance Precede Alterations in Arterial Stiffness Measures in Type 1 Diabetes. <i>Diabetes Care</i> , 2007, 30, 2886-2891.	8.6	41
86	What Is an Angiotensin Converting Enzyme Inhibitor?. <i>Circulation</i> , 2003, 108, e16-8.	1.6	46
87	Nonmalignant Diagnoses in Patients. <i>Journal of Clinical Oncology</i> , 2000, 18, 2638-2639.	1.6	4